Literature DB >> 19896999

Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy.

Gregory M Palmer1, Richard J Boruta, Benjamin L Viglianti, Lan Lan, Ivan Spasojevic, Mark W Dewhirst.   

Abstract

Optical spectroscopy was used to monitor changes in tumor physiology with therapy, and its influence on drug delivery and treatment efficacy for hyperthermia treatment combined with free doxorubicin or a low-temperature sensitive liposomal formulation. Monte Carlo-based modeling techniques were used to characterize the intrinsic absorption, scattering, and fluorescence properties of tissue. Fluorescence assessment of drug concentration was validated against HPLC and found to be significantly linearly correlated (r=0.88). Cluster analysis on the physiologic data obtained by optical spectroscopy revealed two physiologic phenotypes prior to treatment. One of these was relatively hypoxic, with relatively low total hemoglobin content. This hypoxic group was found to have a significantly shorter time to reach 3 times pre-treatment volume, indicating a more treatment resistant phenotype (p=0.003). Influence of tumor physiology was assessed in more detail for the liposomal doxorubicin+hyperthermia group, which demonstrated a highly significant correlation between pre-treatment hemoglobin saturation and tumor growth delay, and also between post-hyperthermia total hemoglobin content and tumor drug delivery. Finally, it was found that the doxorubicin concentration, measured in vivo using fluorescence techniques significantly predicted for chemoresponse (hazard ratio: 0.34, p=0.0007). The ability to characterize drug delivery and tumor physiology in vivo makes this a potentially useful tool for evaluating the efficacy of targeted delivery systems in preclinical studies, and may be translatable for monitoring and predicting individual treatment responses in the clinic. (c) 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19896999      PMCID: PMC2833231          DOI: 10.1016/j.jconrel.2009.10.034

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  30 in total

1.  Optical biopsy of breast tissue using differential path-length spectroscopy.

Authors:  Robert L P van Veen; Arjen Amelink; Marian Menke-Pluymers; Carmen van der Pol; Henricus J C M Sterenborg
Journal:  Phys Med Biol       Date:  2005-05-18       Impact factor: 3.609

2.  Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects.

Authors:  Ana M Ponce; Benjamin L Viglianti; Daohai Yu; Pavel S Yarmolenko; Charles R Michelich; Janet Woo; Marcel B Bally; Mark W Dewhirst
Journal:  J Natl Cancer Inst       Date:  2007-01-03       Impact factor: 13.506

3.  A robust Monte Carlo model for the extraction of biological absorption and scattering in vivo.

Authors:  Janelle E Bender; Karthik Vishwanath; Laura K Moore; J Quincy Brown; Vivide Chang; Gregory M Palmer; Nirmala Ramanujam
Journal:  IEEE Trans Biomed Eng       Date:  2009-04       Impact factor: 4.538

4.  Time- and concentration-dependent penetration of doxorubicin in prostate tumors.

Authors:  J H Zheng; C T Chen; J L Au; M G Wientjes
Journal:  AAPS PharmSci       Date:  2001

5.  Doxorubicin gradients in human breast cancer.

Authors:  J Lankelma; H Dekker; F R Luque; S Luykx; K Hoekman; P van der Valk; P J van Diest; H M Pinedo
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

Review 6.  Mitochondrial NADH as the bellwether of tissue O2 delivery.

Authors:  Britton Chance; Shoko Nioka; Warren Warren; Gunay Yurtsever
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

Review 7.  Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.

Authors:  Peter Vaupel
Journal:  Oncologist       Date:  2008

8.  Deciphering the fluorescence signature of daunomycin and doxorubicin.

Authors:  K K Karukstis; E H Thompson; J A Whiles; R J Rosenfeld
Journal:  Biophys Chem       Date:  1998-07-27       Impact factor: 2.352

9.  Diagnosis of breast cancer using fluorescence and diffuse reflectance spectroscopy: a Monte-Carlo-model-based approach.

Authors:  Changfang Zhu; Gregory M Palmer; Tara M Breslin; Josephine Harter; Nirmala Ramanujam
Journal:  J Biomed Opt       Date:  2008 May-Jun       Impact factor: 3.170

10.  Comparison of a physical model and principal component analysis for the diagnosis of epithelial neoplasias in vivo using diffuse reflectance spectroscopy.

Authors:  Melissa C Skala; Gregory M Palmer; Kristin M Vrotsos; Annette Gendron-Fitzpatrick; Nirmala Ramanujam
Journal:  Opt Express       Date:  2007-06-11       Impact factor: 3.894

View more
  19 in total

1.  Copper-doxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity.

Authors:  Azadeh Kheirolomoom; Lisa M Mahakian; Chun-Yen Lai; Heather A Lindfors; Jai Woong Seo; Eric E Paoli; Katherine D Watson; Eric M Haynam; Elizabeth S Ingham; Li Xing; R Holland Cheng; Alexander D Borowsky; Robert D Cardiff; Katherine W Ferrara
Journal:  Mol Pharm       Date:  2010-12-06       Impact factor: 4.939

Review 2.  Control dominating subclones for managing cancer progression and posttreatment recurrence by subclonal switchboard signal: implication for new therapies.

Authors:  Shengwen Calvin Li; Katherine L Lee; Jane Luo
Journal:  Stem Cells Dev       Date:  2011-11-02       Impact factor: 3.272

3.  Experimental validation of an inverse fluorescence Monte Carlo model to extract concentrations of metabolically relevant fluorophores from turbid phantoms and a murine tumor model.

Authors:  Chengbo Liu; Narasimhan Rajaram; Karthik Vishwanath; Tony Jiang; Gregory M Palmer; Nirmala Ramanujam
Journal:  J Biomed Opt       Date:  2012-07       Impact factor: 3.170

Review 4.  Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes.

Authors:  Mark W Dewhirst; Chelsea D Landon; Christina L Hofmann; Paul R Stauffer
Journal:  Surg Oncol Clin N Am       Date:  2013-03-13       Impact factor: 3.495

5.  Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer.

Authors:  Chelsea D Landon; Ji-Young Park; David Needham; Mark W Dewhirst
Journal:  Open Nanomed J       Date:  2011-01-01

6.  Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.

Authors:  Fan Zhou; Juan Hu; Jiang-Hua Shao; Shu-Bing Zou; Shun-Li Shen; Zhi-Qiang Luo
Journal:  J Cancer Res Clin Oncol       Date:  2012-06-27       Impact factor: 4.553

7.  FOXQ1 controls the induced differentiation of melanocytic cells.

Authors:  Archis Bagati; Anna Bianchi-Smiraglia; Sudha Moparthy; Kateryna Kolesnikova; Emily E Fink; Masha Kolesnikova; Matthew V Roll; Peter Jowdy; David W Wolff; Anthony Polechetti; Dong Hyun Yun; Brittany C Lipchick; Leslie M Paul; Brian Wrazen; Kalyana Moparthy; Shaila Mudambi; Galina E Morozevich; Sofia G Georgieva; Jianmin Wang; Gal Shafirstein; Song Liu; Eugene S Kandel; Albert E Berman; Neil F Box; Gyorgy Paragh; Mikhail A Nikiforov
Journal:  Cell Death Differ       Date:  2018-02-20       Impact factor: 15.828

8.  Near-simultaneous quantification of glucose uptake, mitochondrial membrane potential, and vascular parameters in murine flank tumors using quantitative diffuse reflectance and fluorescence spectroscopy.

Authors:  Caigang Zhu; Hannah L Martin; Brian T Crouch; Amy F Martinez; Martin Li; Gregory M Palmer; Mark W Dewhirst; Nimmi Ramanujam
Journal:  Biomed Opt Express       Date:  2018-06-27       Impact factor: 3.732

Review 9.  Imaging tumor hypoxia to advance radiation oncology.

Authors:  Chen-Ting Lee; Mary-Keara Boss; Mark W Dewhirst
Journal:  Antioxid Redox Signal       Date:  2014-03-24       Impact factor: 8.401

Review 10.  Nanotechnologies for noninvasive measurement of drug release.

Authors:  Thomas Moore; Hongyu Chen; Rachel Morrison; Fenglin Wang; Jeffrey N Anker; Frank Alexis
Journal:  Mol Pharm       Date:  2013-11-26       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.